Back to top
more

Acadia Healthcare (ACHC)

(Delayed Data from NSDQ)

$70.28 USD

70.28
612,938

+0.03 (0.04%)

Updated Apr 18, 2024 04:00 PM ET

After-Market: $70.31 +0.03 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Hospital

Better trading starts here.

Zacks News

Acadia Healthcare (ACHC) Opens Facility to Address Mental Health

Acadia Healthcare (ACHC) inaugurates an acute care hospital in Mesa, AZ, to cater to patients struggling with addiction and mental health issues in the area.

Compelling Reasons to Hold Acadia Healthcare (ACHC) Stock Now

Growing commercial, Medicare and Medicaid revenues will likely boost Acadia Healthcare's (ACHC) top line.

Acadia (ACHC) and Uber Health to Enhance Patient Access

Acadia (ACHC) partners with Uber Health to ensure timely access to addiction treatment, breaking down transportation barriers for patients.

Acadia (ACHC) Buys CTCs to Boost Care Access in North Carolina

Acadia Healthcare (ACHC) acquires three CTCs in the Raleigh, Greenville and Hillsborough regions of North Carolina, therefore increasing its CTC nationwide footprint and fetching improved revenues.

Acadia (ACHC) Starts Construction of Malden's JV Facility

Acadia Healthcare (ACHC) initiates the construction work of the 144-bed Massachusetts-based joint venture hospital in a bid to address the need for efficient behavioral health services in the region.

Why Is Acadia Healthcare (ACHC) Down 6.1% Since Last Earnings Report?

Acadia Healthcare (ACHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Acadia Healthcare (ACHC) Q4 Earnings Beat on Strong Admissions

Acadia Healthcare's (ACHC) Q4 results gain on strong growth in revenue per patient day. It expects adjusted EPS of $3.40-$3.70 for 2024, the mid-point of which implies a 3.2% rise from the 2023 reported figure.

Acadia Healthcare (ACHC) Q4 Earnings and Revenues Surpass Estimates

Acadia Healthcare (ACHC) delivered earnings and revenue surprises of 6.25% and 1.90%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Can Rising Operating Costs Affect Acadia's (ACHC) Q4 Earnings?

Acadia Healthcare's (ACHC) fourth-quarter results are likely to reflect increasing patient days and admissions.

Community Health Systems (CYH) Reports Q4 Loss, Tops Revenue Estimates

Community Health Systems (CYH) delivered earnings and revenue surprises of -1,466.67% and 0.85%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

InspireMD's (NSPR) CE Mark Recertification to Boost CGuard EPS

InspireMD's (NSPR) CE Mark Recertification under MDR is likely to help the company boost the CGuard EPS for carotid artery revascularization care along with advancing with new products.

CONMED (CNMD) Misses on Q4 Earnings, Beats Revenue Estimates

CONMED's (CNMD) adjusted fourth-quarter earnings misses while sales beat estimates on the back of strong growth in the United States and international markets. Gross margin improves with a rise in sales.

Philips' (PHG) New Innovation to Enhance Cardiovascular Imaging

Philips' (PHG) latest X11-4t Mini 3D TEE transducer is likely to have an edge over the traditional 3D TEE in terms of catering to a broader range of patients and improved overall comfort.

Strength Seen in Tenet (THC): Can Its 7.7% Jump Turn into More Strength?

Tenet (THC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

LabCorp (LH) Unveils Test for Preeclampsia in Pregnant Women

LabCorp (LH) test System, which is available through clinicians, is the first FDA-cleared biomarker test to aid in the risk assessment of progression to severe preeclampsia.

Revvity (RVTY) Q4 Earnings Top, EPS View Above Expectation

Revvity's (RVTY) fourth-quarter results showcase the decline in segmental revenues. However, the company's earnings and revenues beat their respective estimates.

Cardinal Health (CAH) Buys Specialty Networks to Boost Workflow

Cardinal Health (CAH) acquires Specialty Network to technologically strengthen its specialty therapeutic areas. The acquisition also supports the company's ongoing Navista Network.

Cardinal Health (CAH) Beats on Q2 Earnings, Ups '24 EPS View

Cardinal Health's (CAH) second-quarter fiscal 2024 results benefit from the Pharmaceutical segment's solid performance.

Thermo Fisher (TMO) Q4 Earnings Top Estimates, Gross Margin Down

Strength in PPI business contributed to Thermo Fisher's (TMO) fourth-quarter revenue growth.

Here's Why You Should Retain Hologic (HOLX) Stock for Now

Investors are optimistic about Hologic (HOLX) owing to its strength in the Breast Health and GYN Surgical segments.

Stryker's (SYK) Q4 Earnings & Revenues Surpass Estimates

Stryker's (SYK) fourth-quarter earnings reflect strong performance across its segments and geographies. Operating and gross margins increased, with earnings and revenues beating estimates.

Cencora (COR) Beats on Q1 Earnings & Revenues, Ups 2024 Outlook

Cencora's (COR) first-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.

Here's Why You Should Retain Neogen (NEOG) Stock for Now

Investors are optimistic about Neogen (NEOG) on strong growth in Animal and Food Safety businesses.

Charles River (CRL) Launches Animal-Free Endotoxin Test

Charles River's (CRL) latest launch expands on Charles River's existing Trillium rCR vial product.

ClearPoint's (CLPT) Neuro Systems to Boost Neurosurgeries

ClearPoint (CLPT) is likely to provide effective neurosurgical operations with the installation of the ClearPoint Prism Neuro Laser Therapy System and the Neuro Navigation System.